Innovative biotechnology to promote health
AMBIOACTIVE Peptide Engineering is a modern biotech start-up, that uses AI-supported biomedical research and sustainable biotechnology to make functional proteins and bioactive peptides accessible for the support of human health
Learn moreApproach
Using our cutting-edge technology, we develop safe and highly bioactive peptides and proteins, that bridge the gap between conventional supplements and specialized therapeutics.
Applications
Healthy Aging
We develop peptides, that combat age-related muscle loss and connective tissue deterioration, while slowing the aging process through their antioxidant effect.
Sport Science and Regeneration
We create peptides, that enhance the regeneration of muscles and tendons post-exercise.
Neurological and cognitive health
We work on peptides, that can minimize trauma and/or age-related brain injury, while simultaniously promoting the energy supply of neurons.
Metabolic and hormonal health
Similar to the appetite-regulating peptide hormone GLP-1, we are working on proteins, that can influence energy balance, including glucose and fatty acid metabolism.
Technological fields
Our research focuses on the development of bioactive peptides with a precisely defined structure and enhanced bioavailability.
Our research and development activities
Maintenance
and growth of
muscular tissue
Formation and
protection of
cartilage
Exercise and
regeneration
Kidney function
(CKD)
Inflammation
and Immunity
Neuro
protection and
cognitive
performance
AMBIOACTIVE® Peptide Engineering operates as a specialized peptide research unit in close cooperation with AMSPORT GmbH. Our mission is the biotechnological development of recombinant proteins with precisely defined bioactive functions.
We focus on the creation of innovative functional “neoproteins” that deliver targeted physiological benefits. Our expertise lies in developing peptides that promote muscle growth and regeneration, strengthen connective tissue and structural integrity, reduce inflammation, and offer nephroprotective as well as neuroprotective effects.
The core of our work lies in a systematic, multi-step development process.
- Identification of bioactive peptide sequences in food-based proteins.
In the first step, we use advanced bioinformatic tools and knowlegd from structural biology to identify peptide regions in known proteins that deliver the desired effects—such as antioxidant, muscle-supporting, or anti-inflammatory activity. We then validate these findings against existing scientific literature to ensure accuracy and reliability.
- Selection and protein design
Using AI-driven algorithms, we transform these peptide subsequences into a completely new protein scaffold—our so-called “neoprotein.” This creates a functional fusion protein designed to release its bioactive components during digestion, ensuring outstanding bioavailability and maximum effectiveness.
- Protein production in yeast
We use the methylotrophic yeast strain Pichia pastoris—simply called Pichia—to manufacture our proteins. As a proven expression system for industrial recombinant proteins, Pichia offers exceptional efficiency and reliability. By integrating the gene containing the blueprint for our “neoprotein” into Pichia’s DNA, the yeast begins producing the desired protein in high yield during fermentation. Unlike conventional protein extraction from natural sources, this biotechnological process is vegan, sustainable, and exceptionally safe.
- Purification and quality assessment
Because Pichia naturally secretes the produced proteins into the culture medium, purification becomes remarkably straightforward, allowing us to achieve high purity using established methods such as ultrafiltration. For precise protein characterization, we rely on advanced analytical techniques including mass spectrometry and gel electrophoresis. The efficacy and biological activity of our proteins are then validated in dedicated cellular bioassays, ensuring reliable and scientifically sound results.
- Scientific validation and application
Our mission goes far beyond producing simple proteins. We develop highly functional bioactive peptides that redefine the boundaries between traditional nutrition, modern dietary supplements, and therapeutic innovation. Through state-of-the-art biotechnological processes, our products are created sustainably, backed by science, and with exceptional purity—ensuring consistently outstanding quality, completely independent of fluctuations in raw materials.
Mit AMBIOACTIVE® haben wir eine Plattform geschaffen, welche die Vorteile moderner Proteinbiotechnologie für Ernährung und Gesundheit nutzbar macht.
Vegan, safe, scientifically validated, and technologically advanced.
Our recombinant proteins serve as high-quality functional food proteins with superior bioactivity and as a powerful foundation for innovative dietary supplements with precisely targeted physiological effects.
Looking ahead, we also view this technology as a bridge toward protein-based prevention and therapy—in line with established biotechnological medicines such as recombinant insulin, erythropoietin, or interferons, which already support and treat millions of patients worldwide.
Our first two neoproteins have already been successfully expressed and are currently undergoing functional characterization in advanced cellular test systems.
HL-MC28 is a patented, biotechnologically engineered protein based on the bioactive peptide sequences of all 28 human collagens. It mirrors the full diversity of human collagen in an optimized structure, opening entirely new possibilities for tissue regeneration and biomedical research.
BPL-30 is a bioactive peptide composition inspired by 30 different natural food sources—including whey, collagen, tuna, mussels, and even the thick-bellied seahorse. This broad peptide spectrum provides a rich functional library with relevance for nutrition, metabolism, and cellular regulation.
All of our proteins are produced sustainably and are 100% vegan.
Scientific Targeted Effective
Mark Warnecke
MD, Nutritional Scientist and CEO of AMSPORT
Dr. Linnea Tscheuschner
R&D Lead
Biotechnology and Biomedical Engineering